Seer (SEER) Competitors

$1.77 +0.09 (+5.36%)

Closing price 04:00 PM Eastern

Extended Trading

$1.74 -0.02 (-1.41%)

As of 06:38 PM Eastern

SEER vs. LAB, NAUT, MASS, PRE, and OPTX

Should you buy Seer stock or one of its competitors? MarketBeat compares Seer with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Seer include Standard BioTools (LAB), Nautilus Biotechnology (NAUT), 908 Devices (MASS), Prenetics Global (PRE), and Syntec Optics (OPTX). These companies are all part of the "measuring and control equipment" industry.

How does Seer compare to Standard BioTools?

Standard BioTools (NASDAQ:LAB) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

In the previous week, Seer had 3 more articles in the media than Standard BioTools. MarketBeat recorded 4 mentions for Seer and 1 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 0.00 beat Seer's score of -0.09 indicating that Standard BioTools is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Seer	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Standard BioTools has a net margin of 73.46% compared to Seer's net margin of -464.78%. Standard BioTools' return on equity of -8.18% beat Seer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	73.46%	-8.18%	-6.43%
Seer	-464.78%	-26.58%	-23.51%

Standard BioTools presently has a consensus target price of $1.35, indicating a potential upside of 29.81%. Seer has a consensus target price of $4.00, indicating a potential upside of 125.99%. Given Seer's stronger consensus rating and higher possible upside, analysts clearly believe Seer is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Standard BioTools has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, Seer has a beta of 1.63, suggesting that its stock price is 63% more volatile than the broader market.

53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 75.2% of Seer shares are held by institutional investors. 23.2% of Standard BioTools shares are held by company insiders. Comparatively, 11.3% of Seer shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Seer has lower revenue, but higher earnings than Standard BioTools. Seer is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	4.76	-$74.90M	$0.20	5.20
Seer	$16.58M	6.02	-$73.60M	-$1.24	N/A

Summary

Standard BioTools and Seer tied by winning 8 of the 16 factors compared between the two stocks.

How does Seer compare to Nautilus Biotechnology?

Seer (NASDAQ:SEER) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Seer currently has a consensus target price of $4.00, suggesting a potential upside of 125.99%. Nautilus Biotechnology has a consensus target price of $4.00, suggesting a potential upside of 57.48%. Given Seer's stronger consensus rating and higher possible upside, analysts clearly believe Seer is more favorable than Nautilus Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

75.2% of Seer shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 11.3% of Seer shares are owned by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Seer had 3 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 4 mentions for Seer and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 0.00 beat Seer's score of -0.09 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seer	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nautilus Biotechnology has a net margin of 0.00% compared to Seer's net margin of -464.78%. Seer's return on equity of -26.58% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seer	-464.78%	-26.58%	-23.51%
Nautilus Biotechnology	N/A	-35.04%	-29.16%

Seer has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

Nautilus Biotechnology has lower revenue, but higher earnings than Seer. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$16.58M	6.02	-$73.60M	-$1.24	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A

Summary

Seer beats Nautilus Biotechnology on 10 of the 16 factors compared between the two stocks.

How does Seer compare to 908 Devices?

908 Devices (NASDAQ:MASS) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

908 Devices has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Seer has a beta of 1.63, suggesting that its stock price is 63% more volatile than the broader market.

908 Devices has a net margin of -62.40% compared to Seer's net margin of -464.78%. 908 Devices' return on equity of -14.03% beat Seer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
908 Devices	-62.40%	-14.03%	-10.40%
Seer	-464.78%	-26.58%	-23.51%

88.1% of 908 Devices shares are owned by institutional investors. Comparatively, 75.2% of Seer shares are owned by institutional investors. 28.2% of 908 Devices shares are owned by company insiders. Comparatively, 11.3% of Seer shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

908 Devices has higher revenue and earnings than Seer. 908 Devices is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$56.20M	4.79	$19.49M	-$1.00	N/A
Seer	$16.58M	6.02	-$73.60M	-$1.24	N/A

908 Devices currently has a consensus price target of $12.00, suggesting a potential upside of 68.54%. Seer has a consensus price target of $4.00, suggesting a potential upside of 125.99%. Given Seer's stronger consensus rating and higher probable upside, analysts clearly believe Seer is more favorable than 908 Devices.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Seer had 1 more articles in the media than 908 Devices. MarketBeat recorded 4 mentions for Seer and 3 mentions for 908 Devices. 908 Devices' average media sentiment score of 0.97 beat Seer's score of -0.09 indicating that 908 Devices is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
908 Devices	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Seer	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

908 Devices beats Seer on 10 of the 17 factors compared between the two stocks.

How does Seer compare to Prenetics Global?

Seer (NASDAQ:SEER) and Prenetics Global (NASDAQ:PRE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Seer had 2 more articles in the media than Prenetics Global. MarketBeat recorded 4 mentions for Seer and 2 mentions for Prenetics Global. Prenetics Global's average media sentiment score of 0.07 beat Seer's score of -0.09 indicating that Prenetics Global is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seer	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prenetics Global	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

75.2% of Seer shares are owned by institutional investors. Comparatively, 25.0% of Prenetics Global shares are owned by institutional investors. 11.3% of Seer shares are owned by insiders. Comparatively, 7.8% of Prenetics Global shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Prenetics Global has higher revenue and earnings than Seer. Prenetics Global is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$16.58M	6.02	-$73.60M	-$1.24	N/A
Prenetics Global	$92.39M	2.91	-$37.71M	-$4.02	N/A

Prenetics Global has a net margin of -61.33% compared to Seer's net margin of -464.78%. Prenetics Global's return on equity of -19.61% beat Seer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seer	-464.78%	-26.58%	-23.51%
Prenetics Global	-61.33%	-19.61%	-15.33%

Seer has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market. Comparatively, Prenetics Global has a beta of 0.15, suggesting that its share price is 85% less volatile than the broader market.

Seer presently has a consensus price target of $4.00, suggesting a potential upside of 125.99%. Prenetics Global has a consensus price target of $32.33, suggesting a potential upside of 103.10%. Given Seer's stronger consensus rating and higher possible upside, equities research analysts clearly believe Seer is more favorable than Prenetics Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Prenetics Global	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Seer beats Prenetics Global on 10 of the 17 factors compared between the two stocks.

How does Seer compare to Syntec Optics?

Syntec Optics (NASDAQ:OPTX) and Seer (NASDAQ:SEER) are both small-cap measuring and control equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Seer has a consensus target price of $4.00, indicating a potential upside of 125.99%. Given Seer's stronger consensus rating and higher possible upside, analysts plainly believe Seer is more favorable than Syntec Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syntec Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Syntec Optics has higher revenue and earnings than Seer. Syntec Optics is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syntec Optics	$28.08M	14.41	-$1.79M	-$0.08	N/A
Seer	$16.58M	6.02	-$73.60M	-$1.24	N/A

In the previous week, Syntec Optics had 3 more articles in the media than Seer. MarketBeat recorded 7 mentions for Syntec Optics and 4 mentions for Seer. Syntec Optics' average media sentiment score of 0.43 beat Seer's score of -0.09 indicating that Syntec Optics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syntec Optics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Seer	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Syntec Optics has a beta of -0.93, indicating that its stock price is 193% less volatile than the broader market. Comparatively, Seer has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market.

Syntec Optics has a net margin of -10.95% compared to Seer's net margin of -464.78%. Seer's return on equity of -26.58% beat Syntec Optics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syntec Optics	-10.95%	-30.86%	-12.35%
Seer	-464.78%	-26.58%	-23.51%

75.2% of Seer shares are held by institutional investors. 0.8% of Syntec Optics shares are held by insiders. Comparatively, 11.3% of Seer shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Syntec Optics and Seer tied by winning 8 of the 16 factors compared between the two stocks.

Get Seer News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SEER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SEER vs. The Competition

Export

Metric	Seer	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$94.79M	$3.33B	$6.34B	$12.29B
Dividend Yield	N/A	2.29%	2.79%	5.32%
P/E Ratio	-1.43	10.37	17.81	22.73
Price / Sales	6.02	289.26	524.48	77.74
Price / Cash	N/A	129.82	44.13	56.13
Price / Book	0.41	6.90	9.99	7.01
Net Income	-$73.60M	$24.23M	$3.55B	$335.05M
7 Day Performance	1.14%	0.59%	0.42%	-0.29%
1 Month Performance	-11.50%	-0.61%	-0.05%	1.15%
1 Year Performance	-14.90%	63.26%	35.06%	34.79%

Seer Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SEER Seer	3.5509 of 5 stars	$1.77 +5.4%	$4.00 +126.0%	-19.6%	$94.79M	$16.58M	N/A	160
LAB Standard BioTools	2.2591 of 5 stars	$1.01 +2.0%	$1.35 +33.7%	+1.0%	$386.46M	$86.26M	5.05	620
NAUT Nautilus Biotechnology	2.7952 of 5 stars	$2.93 -3.0%	$4.00 +36.5%	+189.5%	$383.78M	N/A	N/A	130	Positive News
MASS 908 Devices	1.9143 of 5 stars	$7.65 -3.5%	$12.00 +56.9%	+41.3%	$299.86M	$56.20M	N/A	60
PRE Prenetics Global	2.3193 of 5 stars	$17.99 +2.5%	$32.33 +79.7%	+111.9%	$296.14M	$92.39M	N/A	1

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SEER) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Seer (SEER) Competitors

SEER vs. LAB, NAUT, MASS, PRE, and OPTX

How does Seer compare to Standard BioTools?

Summary

How does Seer compare to Nautilus Biotechnology?

Summary

How does Seer compare to 908 Devices?

Summary

How does Seer compare to Prenetics Global?

Summary

How does Seer compare to Syntec Optics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEER vs. The Competition

Seer Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Seer (SEER) Competitors

SEER vs. LAB, NAUT, MASS, PRE, and OPTX

How does Seer compare to Standard BioTools?

Does the media favor LAB or SEER?

Is LAB or SEER more profitable?

Do analysts rate LAB or SEER?

Which has more risk and volatility, LAB or SEER?

Do institutionals and insiders believe in LAB or SEER?

Which has better earnings and valuation, LAB or SEER?

Summary

How does Seer compare to Nautilus Biotechnology?

Do analysts prefer SEER or NAUT?

Do insiders & institutionals have more ownership in SEER or NAUT?

Does the media refer more to SEER or NAUT?

Is SEER or NAUT more profitable?

Which has more risk and volatility, SEER or NAUT?

Which has stronger valuation and earnings, SEER or NAUT?

Summary

How does Seer compare to 908 Devices?

Which has more volatility & risk, MASS or SEER?

Is MASS or SEER more profitable?

Do institutionals & insiders have more ownership in MASS or SEER?

Which has higher valuation & earnings, MASS or SEER?

Do analysts prefer MASS or SEER?

Does the media refer more to MASS or SEER?

Summary

How does Seer compare to Prenetics Global?

Does the media favor SEER or PRE?

Do institutionals and insiders have more ownership in SEER or PRE?

Which has stronger earnings & valuation, SEER or PRE?

Is SEER or PRE more profitable?

Which has more risk & volatility, SEER or PRE?

Do analysts prefer SEER or PRE?

Summary

How does Seer compare to Syntec Optics?

Do analysts prefer OPTX or SEER?

Which has better earnings & valuation, OPTX or SEER?

Does the media prefer OPTX or SEER?

Which has more risk & volatility, OPTX or SEER?

Is OPTX or SEER more profitable?

Do institutionals and insiders hold more shares of OPTX or SEER?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEER vs. The Competition

Seer Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools